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ABSTRACT 
 
Resveratrol regulate CXCR4 expression and downstream signaling 
of Caki-1 cells in vivo and in vitro 
 
So-Jung Yoon 
 
Department of Medical Science 
The Graduate School, Yonsei University 
 
(Directed by Professor Sung Joon Hong) 
 
Resveratrol, a phytoestrogen found in food products such as grapes 
and wine, produces various physiological effects.  Resveratrol 
possesses anticancer activity: it inhibits proliferation and induces 
apoptotic cell death in multiple cancers cells.  The chemokine stromal 
cell-derived factor-1α (SDF-1α)/CXCR4 axis plays a prominent role in 
tumorigenesis and promotes angiogenesis and migration of tumor cells 
to metastatic sites in many cancers.  Expression of CXCR4 was shown 
to be upregulated in most renal cell carcinoma (RCC) patients.  In 
human RCC, CXCR4 plays a major role in the proliferation and growth 
of cancer cells through activation of PI3K/AKT signaling. We 
demonstrate that resveratrol suppresses the expression of CXCR4, and 
inhibits cell proliferation and growth of the human kidney cancer cell 
line, Caki-1.  We show that resveratrol suppresses RNA and protein 
expression of CXCR4 in Caki-1 cells by a mechanism involving 
transcriptional regulation.   Recombinant SDF-1α, the ligand of 
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CXCR4, induces cell proliferation and AKT and extracellular signal–
regulated kinase(ERK) 1/2 activation, and can, independently, cause 
renal cell carcinoma cells proliferation.  Resveratrol inhibits cell 
growth and proliferation caused by SDF-1α in Caki-1 cells.  Also, we 
examined the therapeutic efficacy of resveratrol in vivo by treating 
SCID mice bearing Caki-1 cells.  Resveratrol suppressed both tumor 
growth and the expression of CXCR4 in the xenograft model.  These 
data suggest that resveratrol may be a therapeutic agent for kidney 
cancer as an effective inhibitor of CXCR4.  These results may provide 
a new therapeutic strategy for the use of a natural compound in the 
treatment of human kidney cancer. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Key Words: CXCR4, resveratrol, kidney cancer 
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Resveratrol regulate CXCR4 expression and downstream signaling 
of Caki-1 cells in vivo and in vitro 
 
So-Jung Yoon 
 
Department of Medical Science 
The Graduate School, Yonsei University 
 
(Directed by Professor Sung Joon Hong) 
 
I. INTRODUCTION  
 
RCC accounts for approximately 3% of new cancer incidences or 
mortality rate in the Unites States.  RCC is a very heterogeneous 
disease that consists of various subtypes based on genetic and 
morphological features 1, 2.  A broad classification of RCC includes 
several histological subtypes: clear cell, papillary, chromophobe, and 
collecting duct.  The clear cell carcinomas are the most prevalent and 
constitute up to 80-85% of cases.  The clear cell tumors exhibit loss of 
heterozygosity (LOH) and somatic mutation of the Von Hippel-Lindau 
(VHL) tumor suppressor gene.  Because of these features, clear cell 
tumors have an invasive and metastatic phenotype.  At present, 
surgical resection is the most effective treatment for localized RCC.  
Despite continuing investigation and increased understanding of the 
biology of the disease, for the management of advanced or metastatic 
disease there is a lack of effective adjuvant treatment such as 
chemotherapy, radiotherapy, or biologic response modifiers.  Recently, 
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small molecule targeting drugs, small-molecule multi-kinase inhibitors, 
anti-VEGF antibody, and a mammalian target of rapamycin inhibitor 
have been developed, but responses are mostly partial and of limited 
efficacy 3.  
Previous studies have suggested that chemokines may play a major 
role in mediating tumor growth and survival 4, 5.  Chemokines are a 
group of chemoattractant cytokines that mediate several cellular 
functions.  CXC chemokine receptor, fusin, (CXCR4), a seven- 
membrane spanning G protein–coupled receptor, is expressed in 
various cells such as T lymphocytes, monocytes, neutrophils, and 
endothelial cells.  It interacts specifically with SDF-1α, and activation 
of CXCR4 is induced by SDF-1α binding.  Activated CXCR4 induces 
several signaling cascades, including the phosphatidylinostiol 3-kinase 
and mitogen-activated protein kinase cascades, which induce 
cytoskeletal rearrangement, anti-apoptosis effects, and cell growth 6.  
Signal transduction pathways induced by CXCR4 activation stimulate 
cell growth and proliferation in cancer cells.  Research has shown that 
CXCR4 is involved in increasing the metastatic potential of RCC, 
colon, and breast cancer cells.  In RCC, it is known that pVHL 
negatively regulates CXCR4 expression, owing to its capacity to target 
hypoxia-inducing factor-1α (HIF-1α) for degradation under normoxic 
conditions.  This process is suppressed under hypoxic conditions, 
resulting in HIF-1α-dependent CXCR4 activation 7.  The activation of 
HIF-1α and CXCR4 induces the proliferation, growth, and metastatic 
phenotype of RCC.  It has been shown that CXCR4 expression 
correlates with growth and progression of various cancer cell lines, but 
the regulatory mechanism of CXCR4 expression is poorly understood.  
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Resveratrol (3,4',5-trihydroxy-trans-stilbène) is a natural phytoalexin 
present in grapes and a variety of plants, including peanuts, mulberries, 
and legumes 8 .  It has been shown to inhibit growth of several types 
of cancer, including breast cancer, prostate cancer, pancreatic cancer, 
and colon cancer 9.  These studies support the idea that resveratrol 
possesses anti-cancer activity by interfering with different cellular 
events associated with initiation, promotion, and progression of multi-
stage carcinogenesis.  In this report, we investigated whether 
resveratrol influences CXCR4 expression in human kidney cancer cells 
in vitro and in vivo, and also tested whether resveratrol could serve as a 
potential therapeutic agent or adjuvant in the treatment of human 
kidney cancer. 
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II. MATERIALS AND METHODS 
Reagents 
Resveratrol (>99% pure) was purchased from Sigma-Aldrich (St. 
Louis, MO) and dissolved in absolute ethanol.  
Cell culture 
The human RCC cell lines, Caki-1 was obtained from the American 
Type Culture Collection (ATCC, Manassas, VA). Cell cultures were 
maintained in McCoy’s 5A medium containing 10% fetal bovine serum 
(FBS; Invitrogen, Carlsbad, CA), 100 units/ml penicillin, and 100 
mg/ml streptomycin (Invitrogen). 
Reverse transcription-PCR analysis 
Total RNA was isolated from cultured cells using the TRIzol reagent 
(Invitrogen) according to the manufacturer’s protocol. For quantitative 
RT-PCR, cDNAs were synthesized from 4 μg of total RNA using oligo 
primers and SuperScript reverse transcriptase II (Invitrogen) according 
to the manufacturer’s protocol. The resulting cDNA 1 μl was 
subsequently used in RT-PCR. The DNA was amplified for 25 cycles 
using CXCR4 primers: CXCR4 5’ primer, 5’-
TAACTACACCGAGGAAATGGGCTCA-3’ and 3’ primer, 5’-
GTTAGCTGGAGTGAAAACTTGAAGACTCAG-3’ ; 
glyceraldehydes-3-phosphate dehydrogenase (GAPDH) 5’ primer, 5’-
CCCCTTCATTGA-CCTTCAACTA-3’ and 3’ primer, 5’-
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GAGTCCTTCCACGATACCAAAG-3’. As an invariant control, 
GAPDH was used. Each PCR cycle was carried out for 30 sec at 94 °C, 
30 sec at 57.5 °C and 1 min 30 sec at 72 °C. PCR products were then 
separated electrophoretically in a 1% agarose DNA gel and stained 
with ethidium bromide. 
Immunoblot analysis 
Caki-1 cells were seeded in 100mm dish in media containing 10% 
FBS at a density of 1 x 106 cells/dish. Two days later, the cells were 
incubated with 50 and 100 μM resveratrol for 48 hr. The cells were 
harvested using diluted Laemmli buffer and then briefly sonicated. 
Total cell lysates were centrifuged at 12000 rpm for 10min 4 °C. 
Supernatants were collected and determine protein concentration, using 
a modified Bradford assay kit. The proteins (40 or 45μg) were 
separated in 8~10% SDS–polyacrylamide gel electrophoresis (SDS–
PAGE) and then transferred to Protran nitrocellulose membranes 
(Schleicher & Schuell, Dassel, Germany). Membranes were blocked in 
5% nonfat dry milk solution in Tris-buffered saline containing 0.1% 
Tween-20 (TBST) for overnight and incubated for 3 hr with the 
primary antibody diluted in TBST, and then incubated with 1:5,000 
diluted solution of ImmunoPure HRP conjugated goat anti-rabbit or 
anti-mouse IgG antibody (Cat. No. # 31462 or # 31430, Santa Cruz 
BiotechnologyInc., Santa Cruz, CA) at room temperature for 20 min. 
The immuno-reactive bands were visualized with the SuperSignal West 
Pico Chemiluminescent System (Pierce, Rockford, IL). The specific 
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bands were detected against phosphorylated forms of AKT and ERK 
and CXCR4, native AKT, PI3K, ERK and β-actin (Santa Cruz).  
Recombinant plasmids 
The CXCR4 promoter was constructed by sub-cloning from the 
genomic DNA of Caki-1 cells using the follow primer; 5’ primer, 5’-
GGCAGCTTATAGAGAACCACCTTGTAA-3’ and 3’ primer, 5’-
TTTAAAATTCACCAAATTCTTTTGCA-3’. The resulting 2kb 
fragment for the CXCR4 promoter was inserted into the SmaI site of 
pGL3-basic vector (Promega Corp., Madison, WI) and the plasmid 
construct was called as the pCXCR4-Luc reporter. The sequences of 
plasmid were confirmed by DNA sequencing using the RV3 primer 5’-
CTAGCAAAATAGGCTGTCCCC-3’. 
Transient transfections and reporter gene assays. 
Caki-1 cells seeded at 2 x 105 cells/well in 6-well plate were cultured 
with the cell culture medium described above. The next day, the cells 
were transfected with the indicated plasmid DNA using Lipofectamine 
2000 (Invitrogen) according to the manufacturer’s protocol. After 6 hr 
incubation, the medium was changed with 10% FBS containing fresh 
medium. The next day, each three wells treated with or without 50 and 
100 μM resveratrol. After 48 hr incubation, cells were washed with 
PBS and lysed in 200 μl passive lysis buffer (Promega Corp.). Aliquots 
of 5 μl of cleared lysates were used to assay luciferase activity, using a 
luciferase reporter assay kit (Promega Corp.). The values were 
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normalized with protein contents. Each transfection experiment was 
performed in triplicate. 
MTT assay 
The effect of resveratrol on cell proliferation was measured using an 
MTT-based assay. Briefly, the cells (5 x 103 cells / well) were 
incubated in triplicate in a 96-well plate in the presence of various 
concentrations of resveratrol and/or ethanol in a final volume of 0.1 mL 
for 48 hr. The number of viable cells was counted using CellTiter 96® 
Aqueous One Solution Cell Proliferation Assay (Promega, Madison, 
WI) according to the manufacturer’s instructions. Thereafter, 0.02 mL 
of MTT solution was added to each well and then incubated for 4 hr. It 
recorded the absorbance at 490nm using a 96-well plate reader 
(Molecular Devices Corp. Sunnyvale, CA). The following formula was 
used: percentage cell viability = (OD of the experimental samples / OD 
of the control ) x 100 
Treatment of Caki 1-derived xenografts 
Male SCID mice (6-week-old) (Japan SLC, Hamamatsu, Japan) were 
maintained in pathogen-free sterile isolators according to institutional 
guidelines, and all food, water, caging, and bedding were sterilized 
prior to use. Caki-1 cells (5x106 cells) were injected s.c. Tumor volume 
was determined by measuring length, width, and depth of the tumor 
every 1 days using a caliper, which was calculated using the equation: 
tumor volume (cm3) = 0.523 x [length (cm) x width2 (cm2)]. At a tumor 
size of approximately 40 mm3 the mice were divided into two 
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subgroups. One group received daily intraperitoneal injections of 
resveratrol dissolved in ethanol at a dose of 50 mg/kg once every 2 
days for a total of 10 injections while the other group received daily 
injections of vehicle only. Following 3 weeks of treatment, the mice 
were sacrificed and the tumors fixed in 4% paraformaldehyde, 
sectioned. Remaining tumor samples were flash frozen under liquid 
nitrogen and stored at –80°C for resveratrol analysis as described 
below. All protocols for animal studies were reviewed and approved by 
the Institutional Animal Care and Use Committee at Yonsei University. 
Statistical analysis 
All results are expressed as mean ± standard error of the mean (SEM). 
Statistical significance was evaluated with an unpaired Student’s t test 
for comparison between two groups or with analysis of variance for 
comparison between multiple groups using Prism 4 software (Graphpad 
Software, San Diego, CA). A probability value of p<0.05 was 
considered significant. 
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III. RESULTS 
 
Effects of resveratrol on the expression of CXCR4 mRNA and 
protein in Caki-1 cells 
 
To observe the effect of resveratrol on CXCR4 in human kidney 
cancer cells, we selected a representative human kidney cancer cell line, 
Caki-1.  In Caki-1 cells, CXCR4 expression was identified at both the 
mRNA and protein levels.  As shown in Fig. 1A, expression of 
CXCR4 mRNA was suppressed in a dose-dependent manner by 
resveratrol.  Also, we performed immunoblot analysis to confirm 
altered CXCR4 expression in resveratrol-treated Caki-1cells.  
Expression of CXCR4 was completely suppressed in the presence of 
100 µM resveratrol in Caki-1 cells (Fig. 1B).  These experiments 
demonstrate that resveratrol affects CXCR4 expression in Caki-1 cells.  
Because mRNA levels of CXCR4 were decreased by resveratrol, we 
expected that the regulation of CXCR4 expression was dependent on 
transcriptional levels.  In order to identify the regulatory mechanism 
of CXCR4 expression by resveratrol in Caki-1 cells, we generated a 
pCXCR4-Luc reporter construct.  To observe the transcriptional 
regulation of CXCR4, we assessed the responsiveness of the CXCR4 
promoter by resveratrol in Caki-1 cells (Fig. 1C).  CXCR4 promoter 
activity was gradually decreased by a dose-dependent addition of 
resveratrol.  Resveratol at a dose of 100 µM suppressed CXCR4 
promoter activity by 50% in Caki-1 cells.  These results indicate that 
suppression of CXCR4 expression is regulated at the transcriptional 
level in Caki-1 cells. 
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Figure 1. CXCR4 mRNA and protein expression in Caki-1 cells in 
response to resveratrol. (A) Agarose gel (1%) stained with ethidium 
bromide showing the amplified RT-PCR product with equal amounts of 
RNA.  GAPDH was used as the internal control.  Total RNA isolated 
from Caki-1 cells treated with resveratrol for 24 hr.  (B) Caki-1 cells 
were treated for 48 hr with resveratrol and CXCR4 expression was 
determined by western blot analysis.  (C) Caki-1 cells were 
transfected with pCXCR4-Luc reporter construct.  After 6 hr 
transfection, the medium was changed using 10% FBS containing fresh 
medium. The next day, each three wells treated with or without 50 or 
100 μM resveratrol. The luciferase activities were measured at 48 hr 
with resveratrol.  Each transfection experiment was performed in 
triplicate. ***, p < 0.005 versus control value. 
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AKT and ERK-signaling through CXCR4 are inhibited by 
resveratrol in Caki-1 cells 
 
To study the intracellular pathways involved in renal cell carcinoma 
survival, we focused on ERK1/2 activation, which converts 
extracellular stimuli to intracellular signals that control gene expression, 
cell proliferation, and survival, through the SDF-1α/CXCR4 axis 10.  
Another important signal transduction pathway in renal cell carcinoma 
is the PI3K/AKT pathway.  We were interested in whether resveratrol 
could inactivate the ERK1/2 and AKT pathways in Caki-1 cells.  We 
pretreated Caki-1 cells with resveratrol for 48hr and analyzed AKT and 
ERK1/2 activation by western blot.  Our results showed that 
resveratrol inhibited the expression of phosphorylated ERK1/2 as 
compared to the slight activation of ERK1/2 detected under basal 
conditions.  AKT activation also occurred under basal conditions and 
was further decreased after resveratrol stimulation (Fig. 2A).  We then 
assayed by MTT to directly determine the effect of resveratrol on the 
viability in Caki-1 cells.  As shown in Fig. 2B, the viability and 
proliferation of Caki-1 cells were decreased 60% compare to controls 
when treated with resveratrol at concentrations of up to 50 μM.  The 
effects of resveratrol may be exerted through modulation of CXCR4 
gene transcription and rapid signaling by cell surface receptor crosstalk.  
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Figure 2. The effect of resveratrol on AKT and ERK activity and 
cell survival in Caki-1 cells (A) Western blot analysis of 
phosphorylated and total forms of ERK(p44/p42) or AKT (p60) in 
Caki-1 cells that were either untreated or treated-resveratrol. (B) The 
cell viability was measured by the MTT assay.  Cells were cultured for 
24 hr in the absence or presence of resveratrol (25, 50, and 100 μM) for 
48 hr and then assayed. Data are expressed as absorbance at 490 nm. 
***, p < 0.005 versus control value. 
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SDF-1α effects on downstream signaling and cell survival in Caki-1 
Cells 
 
To investigate whether SDF-1α affects downstream signaling and 
cell survival in Caki-1 cells, Caki-1 cells were maintained in serum free 
growth conditions for 24 hr, then treated with SDF-1α for various 
amounts of time.  We found that Caki-1 cells showed peak pERK 
activity after 5 min and diminished over 30 min (Fig. 3A).  The peak 
of pAKT activity also occured after 1min and decreased slightly 10 min 
later.  We then assayed whether SDF-1α influenced the proliferation of 
Caki-1 cells by MTT.  As shown in Fig. 3B, the viability and 
proliferation of Caki-1 cells were increased 50% when treated with 
SDF-1α for 2 days compare to control cells. 
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Figure 3. Activation AKT and ERK by SDF-1α and its effects on 
cell survival  (A) Caki-1 cells were treated with 100 ng/mL SDF-1α 
for 0, 1, 5, 10, and 30 min.  The cell lysates were prepared and used 
for western blot analysis with phospho-AKT, phospho-ERK, total AKT 
or ERK antibody to investigate AKT and ERK activation.  (B) Cells 
were stimulated with SDF-1α for different periods (100 ng/ml). Data 
are expressed as absorbance at OD 490 nm.  Data shown are 
representative of a minimum of three independent experiments. 
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Resveratrol modifies SDF-1α activity of Caki-1 cells 
 
To investigate whether resveratrol could affect the functional 
responsiveness for SDF-1α in Caki-1 cells, we treated cells with 
resveratrol before SDF-1α stimulation.  Caki-1 cells were maintained 
in serum free growth conditions for 24 hr then treated with or without 
resveratrol for 24 hr before stimulation of SDF-1α.  In contrast to 
stimulation of SDF-1α (Fig. 4A), the activity of AKT and ERK was 
strongly diminished as compared to the control group.  Caki-1 cells 
were also maintained in medium with or without resveratrol for 24 hr, 
and 100 ng/mL of SDF-1α was added for 24 hr.  Pre-treatment with 
resveratrol followed by SDF-1α stimulation resulted in OD490 nm 
values lower than that when cells were not pretreated with resveratrol 
(Fig. 4B).  Resveratrol suppressed SDF-1α-mediated proliferation of 
Caki-1 cells in a dose-dependent manner.  
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Figure 4. Resveratrol inhibits AKT and ERK activation induced by 
SDF-1α and cell survival. (A) Caki-1 cells were pretreated with 
100ng/mL resveratrol (50 or 100 μM) for 24 hr before their stimulation 
with SDF-1α for 5 min. The cell lysates were prepared and used for 
western blot analysis with phospho-AKT and ERK antibody to 
investigate AKT and ERK activation. (B) The cell viability was 
measured by the MTT assay. Data are expressed as absorbance at 490 
nm. *, p < 0.01 and ***, p < 0.005 , versus unstimulated cells or versus 
SDF-1α-treated cells in the absence of resveratrol, respectively.  
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Resveratrol inhibits tumor growth and CXCR4 expression in vivo 
 
Because we had shown that resveratrol blocked Caki-1 cell growth 
through the SDF-1α/CXCR4 axis in culture, we further examined the 
therapeutic efficacy of resveratrol in vivo by treating SCID mice 
bearing human RCC Caki-1 tumor xenografts.  As shown in Figure 
5A, tumor volume increased in both groups.  After 28 days, the mean 
volume of the Caki-1 tumor in mice treated with resveratrol at 50 
mg/kg was 120 mm3, whereas that of mice treated with vehicle was 440 
mm3.  Indeed, there was a significant delay in tumor growth in 
animals treated with resveratrol at 50 mg/kg (p < 0.0001). Tumors were 
then harvested from the two groups of mice and were processed for 
western blot analysis for histology.  To confirm that resveratrol 
blocked the PI3K/AKT and ERK pathways in vivo, AKT and ERK 
phosphorylation status were measured by western blot.  The results 
show that, as in vitro in cultured cells, AKT and ERK are present in an 
inactive form in RCC tumors in vivo. Immunoblot analysis clearly 
showed reduction in phosphorylated AKT and ERK levels in tumors of 
resveratrol (50 mg/kg)-treated mice as compared to tumors of control-
treated mice. (Fig. 5B)  Treatment with resveratrol seems to act on the 
inhibition of CXCR4 expression, resulting in inhibition of the CXCR4-
mediated signal pathway. 
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Figure 5. Inhibition of tumor growth and CXCR4 expression after 
resveratrol treatment in Caki-1 cell xenograft model. Caki-1cell 
tumor xenografts were established in nude mice (n = 10).  The linear 
coefficients and standard errors from the random effects model are 
shown in the graph.  (A) Comparison of tumor volumes between 
animals, resveratrol-treated (n = 6) and untreated (n = 4) groups. (B) 
Distribution of CXCR4 and its target gene products in xenograft tumors. 
Western blot analysis was performed for with CXCR4, phospho-AKT, 
AKT, phospho-ERK1/2, and ERK in whole fractions from xenograft 
tumors with resveratrol-treated or untreated mice.   
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Figure6. Resveratrol suppresses tumor growth through the 
inhibition of CXCR4 expression. This diagram was based on this and 
other studies.  The model suggests that resveratrol downregulates 
CXCR4 expression.  Accordingly, it can also inhibit CXCR4- 
mediated downstream signaling and corresponding phenomena such as 
tumor growth.  
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IV. DISCUSSION 
 
Our study showed that resveratrol effectively inhibits in vitro cell 
proliferation and in vivo tumor growth of Caki-1 cells by suppressing 
the expression of CXCR4.  In addition, resveratrol directly affects 
AKT and ERK phosphoryation, and abrogates SDF-1α/CXCR4 
mediated AKT and ERK signaling.  These results indicate that 
resveratrol exerts anti-tumor effects through CXCR4 downregulation.  
Resveratrol, a phytoestrogen found in food products such as grapes 
and wine, causes various physiological effects.  Resveratrol has been 
known as a promising candidate for its chemopreventive effect.  
Resveratrol possesses anticancer activity and inhibits proliferation and 
induces apoptotic cell death in multiple cancers cell types in vitro 11, 12. 
The inhibition of cell cycle and induction of apoptosis are other 
essential features of resveratrol in various cell lines 13-15.  
A complex network of chemokines and receptors exists in the tumor 
microenvironment 5.  Chemokines exert a variety of biological 
functions, including regulation of angiogenesis, activation of cell 
migration, growth promoting effects, and inhibition of apoptosis 6, 16.  
The expression of chemokines and their receptors provides an 
advantage in tumor cells and may supply them with an enhanced ability 
to proliferate and disseminate.  SDF-1α, the ligand for CXCR4, plays 
a major role in tumorigenesis, including tumor growth, invasion, and 
metastasis 17, 18.  The SDF-1α/CXCR4 axis mediates multiple signal 
transduction pathways and a variety of cellular functions, such as cell 
migration, proliferation, and survival.  Sourbier et al. showed that 
SDF-1α/CXCR4 is involved in the PI3K/AKT signaling pathway, 
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which is known to be constitutively active in kidney cancer and 
represents a major target in the prevention of defects in cell growth, 
survival, and motility 19.  We observed that PI3K/AKT and ERK 
signaling is important for SDF-1α/CXCR4-mediated cell growth and 
proliferation in Caki-1 cells, and resveratrol suppresses SDF-
1α/CXCR4 signaling though a decrease in CXCR4 expression in these 
cells.  Our results suggest that resveratrol, as a CXCR4 inhibitor, may 
be effective in inhibiting the growth and proliferation of RCC cells. 
Advanced kidney cancer indicates a more metastatic phenotype than 
other cancers. Because kidney cancer cells have a mutation or loss of 
function of the VHL tumor suppressor gene, the growth and invasion of 
kidney cancer depends on hypoxic conditions.  Several studies have 
suggested that HIF-1α regulates the expression of CXCR4 in RCC.  
These studies further suggest that the loss or functional inactivation of 
the protein product of VHL results in persistent activation of HIF-1α 
and a dramatic increase in CXCR4 20, 21.  Thus, elevated CXCR4 
expression has been detected in several human RCC cell lines and 
tumor samples, while only minimal CXCR4 expression has been 
detected in normal kidney tissues 18, 22.  Some studied also 
demonstrated that hypoxia, leading to increased HIF-1α, is critical for 
the regulation of the expression of CXCR4, and may represent a 
general scheme in tumor metastasis23.  Thus, the expression of 
CXCR4 is activated in a tumor environment by HIF-1α, and the 
hypoxia-induced CXCR4 activates the PI3K/AKT and ERK signaling 
pathways in kidney cancer.  The growth and proliferation of kidney 
cancer cells may be more dependent on CXCR4 signaling in hypoxic 
condition.  Therefore, resveratrol may be more effective in 
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suppressing the growth and proliferation of kidney cancer cells than 
other cancer cells.  In our Caki-1cell tumor xenografts, the expression 
of CXCR4 is completely suppressed by resveratrol.  Also, CXCR4 
mediated PI3K/AKT and ERK signaling are suppressed by resveratrol.  
These results demonstrate that CXCR4 inhibition by resveratrol is 
effective in vivo and resveratrol may be a chemotherapeutic agent, as a 
CXCR4 inhibitor in kidney cancer. 
In conclusion, our studies demonstrate for the first time the 
importance of resveratrol and its effect on CXCR4-expressing RCC 
cells.  Resveratrol effectively inhibited in vitro cell proliferation and 
in vivo tumor growth of Caki-1 cells.  In addition, resveratrol directly 
affected AKT and ERK phosphorylation, and abrogated SDF-
1/CXCR4-mediated AKT and ERK signaling.  However, it remains to 
be determined whether AKT and ERK activity are direct targets of 
resveratrol, diminished via CXCR4 signaling.  Further studies are 
needed using small molecule antagonists for CXCR4, such as 
AMD3100, and RNA interference, in RCC to understand the effects of 
resveratrol on CXCR4-mediated signaling. 
These results indicate that resveratrol can improve its anti-tumor 
effect through CXCR4 downregulation.  Therefore, we suggest that 
resveratrol can be a potential therapeutic agent or adjuvant in the 
treatment of human kidney cancer. 
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V. CONCLUSION 
 
1. Effects of resveratrol on the expression of CXCR4 mRNA and 
protein 
 
2. AKT and ERK-signaling through the CXCR4 are inhibited by 
resveratrol in Caki-1 cells. 
 
3. SDF-1α affects on downstream signaling and cell survival in 
Caki-1 Cells. 
 
4. Resveratrol modifies the SDF-1α activity of Caki-1 cells. 
 
5. Resveratrol inhibits tumor growth and CXCR4 expression in vivo. 
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ABSTRACT (IN KOREAN) 
 
신장 암세포와 동물모델에서 Resveratrol 에 의한 CXCR4 의 
발현 및 downstream signaling 의 활성 억제  
 
지도교수 홍 성 준  
 
연세대학교 대학원 의과학과  
 
윤 소 정  
 
Chemokine stromal cell-derived factor-1/CXCR4 axis 은 
종양형성에 중요하고 혈관 신 생성 및 전이부위로의 암세포 
이동 유도, 세포사멸 억제하는 등 다양한 생물학적 역할을 
한다. 정상의 신장조직과 비교하였을 때 대부분의 RCC 내 
CXCR4 의 발현이 높게 나타났다. 또한 여러 암세포에서 SDF-
1/CXCR4 axis 을 통한 PI3K/AKT 와 ERK signaling 의 활성으로 
암세포의 성장과 분열이 확인되었다.  
Resveratrol 은 포도, 와인 및 다양한 식물에서 발견되는 
phytoestrogen 으로써, 암의 생성 3 단계(initiation, promotion, 
progression) 에 모두 작용하여 암의 성장을 방해 및 억제하는 
것으로 다양한 암세포와 이식 동물모델에서 밝혀지고 있다.  
이에 본 연구는 신장 암 세포의 하나인 Caki-1 cell 과 동물 
모델을 이용하여 resveratrol 에 의한 CXCR4 발현 및 
downstream signaling 의 활성 억제를 확인하였다. 신장암세포 
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중의 하나인 Caki-1 cells 에서 resveratrol 에 의한 CXCR4 의 
발현 조절은 transcriptional level 에서 일어나는 것을 확인하였고 
mRNA 와 단백질 발현 모두 감소하였다. CXCR4 의 ligand 인 
recombinant SDF-1α 에 의한 AKT 와 ERK signaling 의 활성과 
그에 따른 세포 분열의 유도는 resveratrol 에 의해서 억제됨을 
알 수 있었다. 또한 Caki-1 cell 로 암이 유도된 동물모델에 
resveratrol 50mg/kg 을 3 주 동안 피하주사 하여 resveratrol 의 
치료상 효과를 확인하였다. 비교군과 실험군을 비교하였을 때, 
암의 성장이 억제되었고 암 조직 내 CXCR4 의 발현도 
감소하였다.   
 본 연구를 통해 resveratrol 은 CXCR4 의 발현을 
감소시킴으로써 신장 암을 위한 예방 및 치료 보조제로써 
효과적인 역할을 할 것으로 기대된다.  
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